Bear

Are you saying that for the phase 2 trial, 38% of the dosed 208 subjects had to be screened because of elevated levels of transaminase? And 5% of those 38% eventually had to be taken off of 208? 

And if  that is the case, what Patient numbers do you predict that would translate to for the current phase 3 trial and how would that effect RRR? Also, does this information not contradict the overwhelming post referring to 208 as having “no safety issues”? 

Respecrfuly

DNF